Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026)
Incyte (INCY) reported Depreciation & Amortization (CF) of $23.8 million for Q1 2026, up 6.44% on a YoY basis from $22.4 million in Q1 2025, and down 0.75% quarter-over-quarter from $24.0 million in Q4 2025.
Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Incyte has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $23.8 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 6.44% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $94.7 million (up 5.65% YoY), and the FY2025 full-year result was $93.3 million, up 4.52% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $23.8 million, down from $24.0 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $24.0 million in Q3 2025, with the low at $16.4 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $21.0 million across 5 years, with a median of $21.9 million in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 28.15% — and 2025, when it advanced 1.89%.
- Incyte's Depreciation & Amortization (CF) stood at $18.2 million in 2022, then gained by 19.45% to $21.8 million in 2023, then rose by 4.46% to $22.7 million in 2024, then grew by 5.49% to $24.0 million in 2025, then fell by 0.75% to $23.8 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $23.8 million (Q1 2026), $24.0 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 23.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.80 Mn |
| Mar 31, 2026 | 23.80 Mn |
| Dec 31, 2025 | 23.98 Mn |
| Dec 31, 2025 | 23.98 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 22.92 Mn |
| Jun 30, 2025 | 22.92 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Sep 30, 2024 | 22.52 Mn |
| Sep 30, 2024 | 22.52 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Dec 31, 2023 | 21.76 Mn |
| Dec 31, 2023 | 21.76 Mn |